NCT02516774撤回1 期
A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Recommended dose
研究概览
简要总结
The hypothesis is that the particular richness of ATC's microenvironment in TAMs creates a unique opportunity for using Tumor Necrosis Factor blockade during chemotherapy and radiotherapy in order to counteract tumor resistance to therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically proven anaplastic thyroid cancers (localized or metastatic)
- •Life-expectancy > 12 weeks
- •No previous treatment for anaplastic thyroid cancer excepted surgery or crizotinib
- •Written Informed consent signed
- •Age > 18 years
- •Neutrophil count > 1500 /mm3, Haemoglobin > 9 gr/dL, Platelet count > 100,000/mm3
- •Bilirubin < 1.5 mg/dL, Transaminases < 3 N in absence of liver metastases or <5 N if presence of liver metastases, PT > 70%
- •Creatinine clearance > 50ml/mn (calculated by the MDRD formula)
- •Negative pregnancy test in women of childbearing potential within 14 days prior to treatment initiation (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization). Both men and women (of childbearing potential) who are sexually active, must use adequate contraception, during and for at least 6 months post-treatment.
- •Evaluable disease > 1 cm within the cervico-mediastinal field of radiotherapy according to the Response Evaluation Criteria in Solid Tumors 1.1 criteria
- •Patient affiliated to social security regimen or beneficiary of such regimen
排除标准
- •Prior treatment with anthracyclines
- •Left Ventricular Ejection Fraction (LVEF) < 50%
- •Known allergy to Adalimumab, doxorubicin, cisplatin, carboplatin or paclitaxel
- •Chronic or acute infection < 15 days
- •Pregnant or breastfeeding patients
- •Any other malignancy in the past 5 years except basal cell carcinoma and carcinoma in situ of the cervix
- •Previous and/or active demyelinating disease, such as multiple sclerosis
- •Prior radiotherapy to the neck
- •Concomitant therapy with agents otherwise used in the treatment of cancer (for example methotrexate for rheumatoid arthritis)
- •Chronic (> 3 months) treatment with oral corticosteroids or another immunosuppressant within 15 days prior registration
- •Patients with an active bleeding diathesis or taking an oral vitamin K antagonist (except low-dose Coumadin (warfarin sodium))
- •Other concurrent severe and/or uncontrolled disease which could compromise participation in the study (i.e. uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmia, active ischemic heart disease, myocardial infarction during the previous six months, chronic liver or renal disease, active upper GI tract ulceration)
- •Patient already enrolled in another therapeutic trial involving an investigational substance, and when such a substance has been taken during the previous 4 weeks
- •Chronic Hepatitis B virus and previous viral hepatitis with risk of reactivation, Hepatitis C virus and human immunodeficiency virus 1 or human immunodeficiency virus 2 infection, active or latent tuberculosis infection
- •Persons deprived of their freedom or under guardianship, or for whom it would be impossible to undergo the medical follow-up required by the trial, for geographic, social or psychological reasons Refusal or absence of biopsy (excepted for initial pathological diagnosis) will not constitute an exclusion criterion.
研究组 & 干预措施
Dose escalation
Experimental
Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)
干预措施: Adalimumab (Drug)
结局指标
主要结局
Recommended dose
时间窗: Up to 9 weeks
Two dose levels will be investigated : * Level 1: 20 mg at D1W1, D1W3, D1W5, D1W7 and D1W9. * Level 2: 40 mg at D1W1, D1W3, D1W5, D1W7 and D1W9.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy VolunteersHealthy VolunteersNCT03579823Alvotech Swiss AG24
已完成
2 期
ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)OligoarthritisNCT04154852University of Leeds22
已完成
2 期
A Trial of Tocilizumab in ALS SubjectsALSAmyotrophic Lateral SclerosisLou Gehrig's DiseaseMotor Neuron DiseaseNCT02469896Barrow Neurological Institute22
招募中
不适用
A Study of Adalimumab in Acute Vogt-Koyanagi-Harada DiseaseVogt-Koyanagi-Harada DiseaseAdalimumabNCT05590416Tianjin Medical University15
已完成
1 期
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPCProstate CancerNCT00286793Ascenta Therapeutics76